# A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety

> **NCT04644484** · PHASE3 · COMPLETED · sponsor: **Synermore Biologics (Suzhou) Co., Ltd.** · enrollment: 1000 (actual)

## Conditions studied

- Rabies
- Communicable Disease
- Virus Diseases
- Rhabdoviridae Infections
- Mononegavirales Infections
- RNA Virus Infections

## Interventions

- **BIOLOGICAL:** SYN023
- **BIOLOGICAL:** Human Rabies Immune Globulin (HRIG)
- **BIOLOGICAL:** Rabies Vaccine

## Key facts

- **NCT ID:** NCT04644484
- **Lead sponsor:** Synermore Biologics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-23
- **Primary completion:** 2022-06-24
- **Final completion:** 2022-12-16
- **Target enrollment:** 1000 (ACTUAL)
- **Last updated:** 2023-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04644484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04644484, "A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04644484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*